Chiasma

Chiasma is a biopharmaceutical company developing oral drugs that were previously only available by injection, providing patients with pain-free medications that are self-administered. In June 2015, the company submitted a New Drug Application to the US FDA seeking approval of its lead product, oral octreotide capsules, for the maintenance treatment of adults with acromegaly. Chiasma went public in July 2015.